SAM
ABCL icon

Stansberry Asset Management’s AbCellera Biologics ABCL Stock Holding History

Stansberry Asset Management’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-40,474
Closed -$119K – 129
2024
Q4 		$119K Sell
40,474
-43,463
-52% -$121K 0.02% 123
2024
Q3 		$218K Sell
83,937
-4,473
-5% -$12.4K 0.03% 124
2024
Q2 		$262K Sell
88,410
-4,878
-5% -$18.5K 0.03% 122
2024
Q1 		$423K Sell
93,288
-6,698
-7% -$34.2K 0.06% 110
2023
Q4 		$571K Sell
99,986
-12,481
-11% -$57.8K 0.09% 100
2023
Q3 		$517K Buy
112,467
+9,792
+10% +$59.6K 0.09% 100
2023
Q2 		$663K Buy
102,675
+1,138
+1% +$7.77K 0.12% 87
2023
Q1 		$766K Buy
101,537
+1,361
+1% +$12.4K 0.15% 88
2022
Q4 		$1.01M Buy
100,176
+2,026
+2% +$23.4K 0.21% 80
2022
Q3 		$971K Sell
98,150
-2,365
-2% -$25.9K 0.21% 72
2022
Q2 		$1.07M Sell
100,515
-2,448
-2% -$20.7K 0.23% 68
2022
Q1 		$1M Buy
102,963
+7,048
+7% +$66.7K 0.16% 79
2021
Q4 		$1.37M Buy
95,915
+56,941
+146% +$864K 0.22% 59
2021
Q3 		$781K Buy
+38,974
New +$689K 0.16% 51

Other funds holding ABCL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $116B AUM 61.47% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Stansberry Asset Management's ABCL Position: Q1 2025 in Review

Stansberry Asset Management sold out of AbCellera Biologics (ABCL) in Q1 2025, closing a stake of 40,474 shares — an estimated $119K sold.

Stansberry Asset Management first reported a position in ABCL in Q3 2021 and held it in 14 quarters. The position peaked at $1.37M in Q4 2021. 129 funds tracked by Wall St. Rank hold ABCL as of Q1 2025.

  • Stansberry Asset Management reported no remaining AbCellera Biologics position as of Q1 2025 after selling out during the quarter.
  • Stansberry Asset Management sold 40,474 AbCellera Biologics shares in Q1 2025, an estimated $119K.
  • Stansberry Asset Management first reported a position in AbCellera Biologics in Q3 2021 and held it in 14 quarters.
  • Stansberry Asset Management's AbCellera Biologics position peaked at $1.37M in Q4 2021.
  • 129 funds tracked by Wall St. Rank held AbCellera Biologics as of Q1 2025.

Based on Stansberry Asset Management's 13F filing for Q1 2025, filed 14 May 2025.